References
- Bhogal S, Rogers T, Aladin A, Ben-Dor I, Cohen JE, Shults CC, et al. TAVR in 2023: Who should not get it? Am J Cardiol 2023; 193: 1-18. doi: 10.1016/j. amjcard.2023.01.040
- Leon MB, Smith CR, Mack MJ, Makkar RR, Svensson LG, Kodali SK, et al. Transcatheter or surgical aortic-valve replacement in intermediate-risk patients. N Engl J Med 2016; 374: 1609-20. doi: 10.1056/NEJMoa1514616
- Mack MJ, Leon MB, Thourani VH, Makkar R, Kodali SK, Russo M, et al. Transcatheter aortic-valve replacement with a balloon-expandable valve in low-risk patients. N Engl J Med 2019; 380: 1695-705. doi: 10.1056/NEJMoa1814052
- Deeb GM, Reardon MJ, Chetcuti S, Patel HJ, Grossman PM, Yakubov SJ, et al. 3-year outcomes in high-risk patients who underwent surgical or transcatheter aortic valve replacement. J Am Coll Cardiol 2016; 67: 2565-74. doi: 10.1016/j.jacc.2016.03.506
- Webb JG, Blanke P, Meier D, Sathananthan J, Lauck S, Chatfield AG, et al. TAVI in 2022: remaining issues and future direction. Arch Cardiovasc Dis 2022; 115: 235-42. doi: 10.1016/J.ACVD.2022.04.001
- Zaid S, Atkins MD, Kleiman NS, Reardon MJ, Tang GHL. What’s new with TAVR? An update on device technology. Methodist Debakey Cardiovasc J 2023; 19: 4-14. doi:10.14797/mdcvj.1230
- Halim J, Rooijakkers M, den Heijer P, El Haddad M, van den Branden B, Vos J, et al. Assessing the novel Myval balloon-expandable valve with the evolut valve: A propensity-matched study. J Clin Med 2023; 12: 4213. doi: 10.3390/jcm12134213
- Kalogeras K, Ruparelia N, Kabir T, Jabbour R, Naganuma T, Vavuranakis M, et al. Comparison of the self-expanding Evolut-PRO transcatheter aortic valve to its predecessor Evolut-R in the real world multicenter ATLAS registry. Int J Cardiol 2020; 310: 120-5. doi: 10.1016/j.ijcard.2020.02.070
- Thyregod HGH, Jørgensen TH, Ihlemann N, Steinbrüchel DA, Nissen H, Kjeldsen BJ, et al. Transcatheter or surgical aortic valve implantation: 10-year outcomes of the NOTION trial. Eur Heart J 2024; 45: 1116-24. doi: 10.1093/eurheartj/ehae043
- Sharma SK, Rao RS, Chandra P, Goel PK, Bharadwaj P, Joseph G, et al. First-inhuman evaluation of a novel balloon-expandable transcatheter heart valve in patients with severe symptomatic native aortic stenosis: the MyVal-1 study. EuroIntervention 2020; 16: 421-9. doi: 10.4244/EIJ-D-19-00413
- Sharma SK, Rao RS, Chopra M, Sonawane A, Jose J, Sengottuvelu G. Myval transcatheter heart valve system in the treatment of severe symptomatic aortic stenosis. Future Cardiol 2021; 17: 73-80. doi: 10.2217/fca-2020-0020
- Barki M, lelasi A, Buono A, Maliandi G, Pellicano M, Bande M, et al. Clinical comparison of a novel balloon-expandable versus a self-expanding transcatheter heart valve for the treatment of patients with severe aortic valve stenosis: The EVAL Registry. J Clin Med 2022; 11: 959. doi: 10.3390/jcm11040959
- Moscarella E, lelasi A, Montonati C, Pellegrini D, Pellicano M, Briguglia D, et al. Comparing two-year outcomes of balloon-expandable Myval and selfexpanding Evolut R in severe aortic valve stenosis. Int J Cardiol 2024; 400: 131701. doi: 10.1016/j.ijcard.2023.131701
- Baumbach A, van Royen N, Amat-Santos IJ, Hudec M, Bunc M, Ijsselmuiden A, et al. LANDMARK comparison of early outcomes of newer-generation Myval transcatheter heart valve series with contemporary valves (Sapien and Evolut) in real-world individuals with severe symptomatic native aortic stenosis: a randomised non-inferiority trial. Lancet 2024; 403: 2695-708. doi: 10.1016/S0140-6736(24)00821-3
- Généreux P, Piazza N, Alu MC, Nazif T, Hahn RT, Pibarot P, et al. Valve academic research consortium 3: Updated endpoint definitions for aortic valve clinical research. J Am Coll Cardiol 2021; 77: 2717-46. doi: 10.1016/J. JACC.2021.02.038
- Rheude T, Blumenstein J, Möllmann H, Husser O. Spotlight on the SAPIEN 3 transcatheter heart valve. Med Devices Evid Res 2018; 11: 353-60. doi: 10.2147/MDER.S143897
- Galderisi M, Cosyns B, Edvardsen T, Cardim N, Delgado V, Di Salvo G, et al. Standardization of adult transthoracic echocardiography reporting in agreement with recent chamber quantification, diastolic function, and heart valve disease recommendations: An expert consensus document of the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging 2017; 18: 1301-10. doi: 10.1093/ehjci/jex244
- Mitchell C, Rahko PS, Blauwet LA, Canaday B, Finstuen JA, Foster MC, et al. Guidelines for performing a comprehensive transthoracic echocardiographic examination in adults: Recommendations from the American Society of Echocardiography. J Am Soc Echocardiogr 2019; 32: 1-64. doi: 10.1016/j. echo.2018.06.004
- Delgado-Arana JR, Gordillo-Monge MX, Halim J, De Marco F, Trani C, Martin P, et al. Early clinical and haemodynamic matched comparison of balloon-expandable valves. Heart 2022; 108: 725-32. doi: 10.1136/heartjnl-2021-319349
- Wendler O, Schymik G, Treede H, Baumgartner H, Dumonteil N, Neumann FJ, et al. SOURCE 3: 1-year outcomes post-transcatheter aortic valve implantation using the latest generation of the balloon-expandable transcatheter heart valve. Eur Heart J 2017; 38: 2717-26 doi: 10.1093/eurheartj/ehx294
- Kodali S, Thourani VH, White J, Malaisrie SC, Lim S, Greason KL, et al. Early clinical and echocardiographic outcomes after SAPIEN 3 transcatheter aortic valve replacement in inoperable, high-risk and intermediate-risk patients with aortic stenosis. Eur Heart J 2016; 37: 2252-62. doi: 10.1093/eurheartj/ehw112
- Rheude T, Pellegrini C, Lutz J, Alvarez-Covarrubias HA, Lahmann AL, Mayr NP, et al. Transcatheter aortic valve replacement with balloon-expandable valves: Comparison of SAPIEN 3 Ultra versus SAPIEN 3. JACC Cardiovasc Interv 2020; 13: 2631-8. doi: 10.1016/j.jcin.2020.07.013
- Stinis CT, Abbas AE, Teirstein P, Makkar RR, Chung CJ, Iyer V, et al. Real-world outcomes for the fifth-generation balloon expandable transcatheter heart valve in the United States. JACC Cardiovasc Interv 2024; 17: 1032-44. doi: 10.1016/j.jcin.2024.02.015
- Frangieh AH, Ott I, Michel J, Shivaraju A, Joner M, Mayr NP, et al. Standardized minimalistic transfemoral transcatheter aortic valve replacement (TAVR) using the SAPIEN 3 device: Stepwise description, feasibility, and safety from a large consecutive single-center single-operator cohort. Struct Hear 2017; 1: doi: 10.1080/24748706.2017.1358832
- Santos-Martinez S, Halim J, Castro-Mejía A, De Marco F, Trani C, Martin P, et al. Myval versus alternative balloon- and self-expandable transcatheter heart valves: A central core lab analysis of conduction disturbances. Int J Cardiol 2022; 351: 25-31. doi: 10.1016/j.ijcard.2021.12.049
- van Royen N, Amat-Santos IJ, Hudec M, Bunc M, Ijsselmuiden A, Laanmets P, et al. Early outcomes of the novel Myval THV series compared to SAPIEN THV series and Evolut THV series in individuals with severe aortic stenosis. EuroIntervention 2025; 21: e105-18. doi: 10.4244/EIJ-D-24-00951